In vivo apoptosis of CD8+ lymphocytes in acute myeloid leukemia patients: Involvement of soluble HLA-I and Fas ligand

Leukemia

Volumn 21, Issue 2, 2007, Pages 253-260

  Contini, P ^a   Zocchi, M R ^b   Pierri, I ^a   Albarello, A ^a   Poggi, A ^c  

^a UNIVERSITY OF GENOA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; CYTARABINE; DEATH RECEPTOR; ETOPOSIDE; FAS ANTIGEN; FAS LIGAND; FLUDARABINE; HLA ANTIGEN CLASS 1; IDARUBICIN; MITOXANTRONE; PROTEIN BCL 2; PROTEIN BCL XL; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN DETECTION; APOPTOSIS; ARTICLE; BLOOD LEVEL; CANCER REGRESSION; CANCER STAGING; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; UPREGULATION;

EID: 33846534192     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404494     Document Type: Article

References (37)

1. Zavazava N. Soluble HLA class I molecules: Biological significance and clinical implications. Mol Med Today 1998; 3: 116-121.
2. Bjorkman P, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen HLAβ-A2. Nature 1987; 329: 506-512.
3. Charlton RK, Zmijewski CM. Soluble HL-A7 antigen: Localization in the β-lipoprotein fraction of human serum. Science 1997; 170: 636-637.
4. van Rood J, van Leeuwen A, van Santen M. Anti HL-A2 inhibitor in normal human serum. Nature 1970; 226: 366-367.
5. Grumet F. Report of the Second International Soluble HLA (sHLA) Workshop. Hum Immunol 1994; 40: 153-165.
6. Puppo F, Scudelletti M, Indiveri F, Ferrone S. Serum HLA class I antigens: Markers and modulators of an immune response? Immunol Today 1995; 16: 124-127.
7. Zavazava N, Bottcher H, Mueller-Ruchholtz WM. Soluble MHC class I antigens (sHLA) and anti-HLA antibodies in heart and kidney allograft recipients. Tissue Antigens 1993; 42: 20-26.
8. De Vito-Haynes LD, Jankowska-Gan E, Sollinger HW, Knechtle SJ, Burlingham WJ. Monitoring of kidney and simultaneous pancreas-kidney transplantation rejection by release of donr-specific soluble HLA class I. Hum Immunol 1994; 40: 191-202.
9. Mathew JM, Shenoy S, Phelan D, Lowell J, Howard T, Mohanakumar T. Biochemical and immunological evaluation of donor specific soluble HLA in the circulation of liver transplan recipients. Transplantation 1996; 62: 217-223.
10. Shimura T, Hagihara M, Yamamoto K, Takebebe K, Munkhbat B, Ogoshi K et al. Quantification of serum-soluble HLA class I antigens in patients with gastric cancer. Hum Immunol 1994; 40: 183-186.
11. Shimura T, Tsutsumi S, Hosouchi Y, Kojima T, Ton Y, Yonezu M et al. Clinical significance of soluble form of HLA class I molecule in Japanese patients with pancreatic cancer. Hum Immunol 2001; 62: 615-619.
12. Westhoff U, Fox C, Otto FJ. Soluble HLA class I antigens in plasma of patients with malignant melanoma. Anticancer Res 1998; 18: 3789-3792.
13. Nocito M, Montalban C, Gonzalez-Porque P, Villar LM. Increased soluble serum HLA class I antigens in patients with lymphoma. Hum Immunol 1997; 58: 106-111.
14. Elliot T, Heisen H. Allorecognition of purified major histocompatibility complex glycoproteins by cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1988; 85: 2728-2732.
15. Kane K, Sherman L, Mescher M. Molecular interactions required for triggering alloantigen-specific cytolytic T lymphocytes. J Immunol 1989; 142: 4153-4160.
16. Hausmann R, Zavazava N, Steinmann J, Mueller-Ruchholtz WM. Interaction of papain-digested HLA class I molecules with human alloreactive cytotoxic T lymphocytes (CTL). Clin Exp Immunol 1993; 91: 183-188.
17. Carbone E, Terrazzano G, Colonna M, Tosto L, Piccolella E, Franksson L et al. Natural killer clones recognize specific soluble HLA class I molecules. Eur J Immunol 1996; 26: 683-689.
18. Spaggiari GM, Contini P, Carosio R, Arvigo M, Ghio M, Oddone D et al. Soluble HLA class I molecules induce natural killer cell apoptosis through the engagement of CD8: Evidence for a negative regulation exerted by members of the inhibitory receptor superfamily. Blood 2002; 99: 1706-1714.
19. Spaggiari GM, Contini P, Dondero A, Carosio R, Puppo F, Indiveri F et al. HLA class I induces NK cell apoptosis upon the engagement of killer-activationg HLA class I receptors through FasL-Fas interaction. Blood 2002; 100: 4098-4107.
20. Zavazava N, Kronke M. Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. Nat Med 1996; 2: 1005-1010.
21. +T lymphocytes. Int Immunol 1999; 12: 195-203.
22. Salter RD, Benjamin RJ, Wesley PK, Buxton SE, Garrett TP, Clayberger C et al. A binding site for the T-cell co-receptor CD8 on the α3 domain of HLA-A2. Nature 1990; 345: 41-46.
23. lck, calcium calmodulin kinase II, and calcium-independent protein kinase C signalling pathways and for NF-kB and NF-AT nuclear translocation. J Immunol 2005; 175: 7244-7254.
24. Ferrero E, Belloni D, Contini P, Foglieni C, Ferrero ME, Fabbri M et al. Transendothelial migration leads to protection from starvation-induced apoptosis in CD34+ CD14+ circulating precursors: Evidence for PECAM-1 involvement through Akt/PKB activation. Blood 2003; 101: 186-193.
25. Chao DT, Korsmeyer SJ. Bcl-2 family: Regulators of cell death. Annu Rev Immunol 1998; 16: 395-419.
26. Barnhart BC, Alappat EC, Peter ME. The CD95 type I/typeII model. Semin Immunol 2003; 15: 185-193.
27. Thorburn A. Death receptor-induced cell killing. Cell Signal 2004; 16: 139-144.
28. Calne R, Davies H. Organ graft tolerance: The liver effect. Lancet 1994; 343: 67-68.
29. Rebmann V, Regel J, Stolke D, Grosse-Wilde H. Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol 2003; 13: 371-377.
30. Wiendl H, Mitsdoerffer M, Hofmeister V, Wishhusen J, Bornemann A, Meyermann R et al. A functional role of HLA-G expression in humen gliomas: An alternative strategy of immune escape. J Immunol 2002; 168: 4772-4780.
31. Doubrovina ES, Doubrovin MM, Vider E, Sisson RB, O'Reilly RJ, Dupont B et al. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adencarcinoma. J Immunol 2003; 171: 6891-6899.
32. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005; 12: 228-237.
33. Andreeff M, Jiang S, Zhang X, Konopleva M, Estrov Z, Snell VE et al. Expression of Bcl-2-related genes in normal and AML progenitors: Changes induced by chemotherapy and retinoic acid. Leukemia 1999; 13: 1881-1892.
34. + cells. Br J Haematol 2002; 118: 521-534.
35. Sonneveld P, Nooter K. Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukaemia. Br J Haematol 1990; 75: 208-211.
36. Ross DD, Wooten PJ, Sridara R, Ordonez JV, Lee EJ, Schiffer CA. Enhancement of daunorubicin accumulation, retention and cytotoxicity, by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukaemia. Blood 1993; 82: 1288-1299.
37. Tsimberidou A, Estey E, Cortes J, Thomas D, Faderl S, Verstovsek S et al. Gemtuzumab, fludarabine, cytarabine and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodisplastic syndromes. Cancer 2003; 97: 1481-1487.